Compare Merck & Co., Inc. (MRK) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Under Armour Inc Class A — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Under Armour Inc Class A trades at $5.07 (market cap $2.15B). The key difference: Merck & Co., Inc. is far larger — about 170.4× Under Armour Inc Class A's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| MRK | UAA | |
|---|---|---|
Market Cap | $366.28B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $8.14 |
52-Week Low | $77.60 | $4.17 |
Enterprise Value | $413.04B | $3.13B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Under Armour (UAA) trades at $5.06, down 3.62% on the day, reflecting persistent investor concerns. The stock is technically bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion. Recent news highlights a reduced revenue outlook for fiscal 2027, though cost discipline aims to preserve profitability.
The outlook remains challenging due to weak North American demand and falling revenue projections. Analyst consensus is a 'Hold' with a $6.67 price target, indicating cautious optimism for margin recovery. Key risks include sustained sales weakness and high debt levels. The stock offers potential upside if margin improvements materialize, but near-term headwinds dominate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
